We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Horizon Discovery Sign Cancer Metabolomics Service Agreement with GlaxoSmithKline
News

Horizon Discovery Sign Cancer Metabolomics Service Agreement with GlaxoSmithKline

Horizon Discovery Sign Cancer Metabolomics Service Agreement with GlaxoSmithKline
News

Horizon Discovery Sign Cancer Metabolomics Service Agreement with GlaxoSmithKline

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Horizon Discovery Sign Cancer Metabolomics Service Agreement with GlaxoSmithKline"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Discovery (Horizon) has announced it has signed a commercial service agreement with Global Pharmaceutical company; GlaxoSmithKline relating to its X-MAN technology.

Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to accelerate and economize the discovery on new ‘targeted’ or ‘personalized’ cancer medicines.

The agreement contributes to the identification and characterization of novel biomarkers, disease signatures and therapeutic targets in the field of cancer ‘metabolomics’; a rapidly growing area of translational cancer research.

“Dr Chris Torrance, CEO  of Horizon says “Horizon uses the power of ‘isogenic’ human cancer models to define how tumors in specific cancer patient-populations  become dependent on certain nutrient sources and whether they generate unique metabolite signatures that can be secreted into the bloodstream. In this way, we aim to develop early-detection methods and new classes of ‘personalized’ therapeutics that may starve cancers into submission”
Advertisement